FDA'S Perspectives on Cardiovascular Devices

被引:5
|
作者
Chen, Eric A. [1 ]
Patel-Raman, Sonna M. [1 ]
O'Callaghan, Kathryn [1 ]
Hillebrenner, Matthew G. [1 ]
机构
[1] US FDA, Ctr Devices & Radiol Hlth, Rockville, MD 20850 USA
关键词
FDA; Cardiovascular Devices; Medical Devices;
D O I
10.1007/s12265-009-9096-7
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Food and Drug Administration (FDA) decision process for approving or clearing medical devices is often determined by a review of robust clinical data and extensive preclinical testing of the device. The mission statement for the Center for Devices and Radiological Health (CDRH) is to review the information provided by manufacturers so that it can promote and protect the health of the public by ensuring the safety and effectiveness of medical devices deemed appropriate for human use (Food, Drug & Cosmetic Act, 903(b)(1, 2(C)), December 31, 2004; accessed December 17, 2008 http://www.fda.gov/opacom/laws/fdcact/fdctoc.htm). For high-risk devices, such as ventricular assist devices (VADs), mechanical heart valves, stents, cardiac resynchronization therapy (CRT) devices, pacemakers, and defibrillators, the determination is based on FDA's review of extensive preclinical bench and animal testing followed by use of the device in a clinical trial in humans. These clinical trials allow the manufacturer to evaluate a device in the intended use population. FDA reviews the data from the clinical trial to determine if the device performed as predicted and the clinical benefits outweigh the risks. This article reviews the regulatory framework for different marketing applications related to cardiovascular devices and describes the process of obtaining approval to study a cardiovascular device in a U. S. clinical trial.
引用
收藏
页码:143 / 146
页数:4
相关论文
共 50 条
  • [1] FDA’S Perspectives on Cardiovascular Devices
    Eric A. Chen
    Sonna M. Patel-Raman
    Kathryn O’Callaghan
    Matthew G. Hillebrenner
    Journal of Cardiovascular Translational Research, 2009, 2 : 143 - 146
  • [2] FDA Perspectives on the Regulation of Neuromodulation Devices
    Marjenin, Timothy
    Scott, Pamela
    Bajaj, Anita
    Bansal, Tushar
    Berne, Bernard
    Bowsher, Kristen
    Costello, Ann
    Doucet, John
    Franca, Eric
    Ghosh, Chandramallika
    Govindarajan, Anupama
    Gutowski, Stacie
    Gwinn, Katrina
    Hinckley, Stephen
    Keegan, Erin
    Lee, Hyung
    Mathews, Binoy
    Misra, Sanjay
    Patel, Shyama
    Tang, Xiaorui
    Heetderks, William
    Hoffmann, Michael
    Pena, Carlos
    NEUROMODULATION, 2020, 23 (01): : 3 - 9
  • [3] FDA regulation of cardiovascular devices and opportunities for improvement
    Dhruva, Sanket S.
    Redberg, Rita F.
    JOURNAL OF INTERVENTIONAL CARDIAC ELECTROPHYSIOLOGY, 2013, 36 (02) : 99 - 105
  • [4] FDA regulation of cardiovascular devices and opportunities for improvement
    Sanket S. Dhruva
    Rita F. Redberg
    Journal of Interventional Cardiac Electrophysiology, 2013, 36 : 99 - 105
  • [5] Evidence Strength in FDA Premarket Approval of Cardiovascular Devices
    Kong, David F.
    Hasselblad, Vic
    Krucoff, Mitchell W.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (16): : 1599 - 1600
  • [6] NHLBI/FDA conference on thrombosis and infections with cardiovascular devices
    Wickline, S
    Wu, K
    Didisheim, P
    Anderson, JM
    Budinger, TF
    Fuster, V
    Harker, LA
    Kottke-Marchant, K
    Maki, DG
    Strauss, W
    Callahan, TH
    Watson, JT
    Berson, A
    JOURNAL OF BIOMEDICAL MATERIALS RESEARCH, 1998, 42 (03): : 341 - 346
  • [7] FDA perspective on clinical trial design for cardiovascular devices
    Chen, Eric
    Sapirstein, Wolf
    Ahn, Chul
    Swain, Julie
    Zuckerman, Bram
    ANNALS OF THORACIC SURGERY, 2006, 82 (03): : 773 - 775
  • [8] FDA perspectives on postmarket surveillance of peripheral and aortic vascular devices
    Malone, Misti
    Johnson, Carmen Gacchina
    CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2024, 104 (01) : 170 - 171
  • [9] Evidence Strength in FDA Premarket Approval of Cardiovascular Devices Reply
    Redberg, Rita F.
    Dhruva, Sanket S.
    Bero, Lisa A.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2010, 303 (16): : 1600 - 1601
  • [10] Gender Bias in Studies for FDA Premarket Approval of Cardiovascular Devices
    Dhruva S.S.
    Cullen E.B.
    Redberg R.F.
    Current Cardiovascular Risk Reports, 2014, 8 (7) : 1 - 5